Trastuzumab biosimilar PBS-listed
Among its indications are for patients with HER2-positive advanced adenocarcinoma of the stomach
![woman in pink top wearing pink ribbon to denote breast cancer](https://www.ausdoc.com.au/wp-content/uploads/2022/08/breast_cancer_ribbon_istock-687663218-9.jpg)
A biosimilar of trastusumab, Ogivri (Mylan), was listed on the PBS on 1 August.
The biosimilar is available as a 150mg injection and is indicated for HER2-positive early breast cancer in combination with chemotherapy, and possibly also radiotherapy.